Mustang Bio Announces Orphan Drug Designation for MB-207 for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability